VX-770 IN SUBJECTS 6 TO 11 YEARS WITH CYSTIC FIBROSIS AND THE G551D-CFTR MUTATION

被引：0
|
作者：
Aherns, R. [1 ]
Rodriguez, S. [2 ]
Yen, K. [2 ]
Davies, J. C. [3 ]
机构：
[1] Univ Iowa, Iowa City, IA USA
[2] Vertex Pharmaceut Inc, Cambridge, MA USA
[3] Royal Brompton Hosp, London SW3 6LY, England
来源：
PEDIATRIC PULMONOLOGY | 2011年
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：283 / 283
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF VX-770 IN SUBJECTS WITH CYSTIC FIBROSIS AND THE G551D-CFTR MUTATION
    Ramsey, B.
    Dong, Q.
    Yen, K.
    Elborn, J.
    PEDIATRIC PULMONOLOGY, 2011, : 286 - 287
  • [2] Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
    Accurso, Frank J.
    Rowe, Steven M.
    Clancy, J. P.
    Boyle, Michael P.
    Dunitz, Jordan M.
    Durie, Peter R.
    Sagel, Scott D.
    Hornick, Douglas B.
    Konstan, Michael W.
    Donaldson, Scott H.
    Moss, Richard B.
    Pilewski, Joseph M.
    Rubenstein, Ronald C.
    Uluer, Ahmet Z.
    Aitken, Moira L.
    Freedman, Steven D.
    Rose, Lynn M.
    Mayer-Hamblett, Nicole
    Dong, Qunming
    Zha, Jiuhong
    Stone, Anne J.
    Olson, Eric R.
    Ordonez, Claudia L.
    Campbell, Preston W.
    Ashlock, Melissa A.
    Ramsey, Bonnie W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (21): : 1991 - 2003
  • [3] IMPROVEMENT IN SWEAT CHLORIDE CONCENTRATION BY THE CFTR POTENTIATOR VX-770 IN SUBJECTS WITH CYSTIC FIBROSIS AND THE G551D-CFTR MUTATION
    Accurso, F.
    Rowe, S. M.
    Durie, P. R.
    Konstan, M. W.
    Dunitz, J.
    Hornick, D.
    Sagel, S. D.
    Boyle, M. P.
    Uluer, A. Z.
    Moss, R. B.
    Donaldson, S.
    Pilewski, J.
    Rubenstein, R. C.
    Aitken, M. L.
    Ramsey, B.
    Freedman, S. D.
    Dong, Q.
    Zha, J.
    Stone, A.
    Olson, E. R.
    Ordonez, C.
    Campbell, P.
    Ashlock, M.
    Clancy, J. P.
    PEDIATRIC PULMONOLOGY, 2009, : 296 - 296
  • [4] Case History: Kalydeco® (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CFTR Mutation
    Hadida, Sabine
    Van Goor, Frederick
    Dinehart, Kirk
    Looker, Adam R.
    Mueller, Peter
    Grootenhuis, Peter D. J.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 383 - 398
  • [5] UNRAVELING THE MECHANISM OF VX-770 ON WTAND G551D-CFTR
    Lin, W.
    Jih, K.
    Hwang, T.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 210 - 210
  • [6] EFFECT OF VX-770, A CFTR POTENTIATOR, ON SPIROMETRY AND QOL ASSESSMENT IN SUBJECTS WITH CF AND THE G551D-CFTR MUTATION
    Boyle, M.
    Clancy, J. P.
    Rowe, S. M.
    Durie, P.
    Dunitz, J.
    Konstan, M. W.
    Hornick, D.
    Sagel, S. D.
    Ramsey, B.
    Dong, Q.
    Ordonez, C.
    Campbell, P.
    Ashlock, M.
    Accurso, F. J.
    PEDIATRIC PULMONOLOGY, 2009, : 287 - 287
  • [7] Discovery of VX-770 (Ivacaftor), a CFTR potentiator for the treatment of cystic fibrosis in G551D patients
    Grootenhuis, Peter D. J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [8] Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation
    Sermet-Gaudelus, Isabelle
    EUROPEAN RESPIRATORY REVIEW, 2013, 22 (127): : 66 - 71
  • [9] Population pharmacokinetics and pharmacodynamics of the CFTR potentiator ivacaftor in patients with cystic fibrosis and a G551D-CFTR mutation
    Haseltine, Eric
    Mondick, John
    Garg, Varun
    Lekstrom-Himes, Julie
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S30 - S31
  • [10] NOVEL POTENTIATOR CP-628006 AND VX-770 HAVE DIFFERENT AND ADDITIVE MECHANISMS FOR POTENTIATION OF G551D-CFTR CHANNEL ACTIVITY
    Liu, J.
    Cao, L.
    Berg, A.
    Kim, H.
    Stevens, E.
    Pregel, M.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 210 - 211
12345